Announcements
Expression of concern regarding paper by Park et al, published on 25 June 2015: “Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015”, Euro Surveill. 2015;20(25):pii=21169. It has been brought to our attention that some of the authors may not have been informed about the content of the above paper. There is a lack of clarity regarding rights to use the data. The editorial team are investigating what action needs to be taken.

Follow Eurosurveillance on Twitter: @Eurosurveillanc

Read our articles on Zika virus infection

Read our articles on mcr-1-mediated colistin resistance


In this issue


Home Eurosurveillance Edition  2016: Volume 21/ Issue 2 Article 2
Back to Table of Contents
Previous Download (pdf)
Next

Eurosurveillance, Volume 21, Issue 2, 14 January 2016
Rapid communication
Heudorf, Krackhardt, Karathana, Kleinkauf, and Zinn: Multidrug-resistant bacteria in unaccompanied refugee minors arriving in Frankfurt am Main, Germany, October to November 2015

+ Author affiliations


Citation style for this article: Heudorf U, Krackhardt B, Karathana M, Kleinkauf N, Zinn C. Multidrug-resistant bacteria in unaccompanied refugee minors arriving in Frankfurt am Main, Germany, October to November 2015. Euro Surveill. 2016;21(2):pii=30109. DOI: http://dx.doi.org/10.2807/1560-7917.ES.2016.21.2.30109

Received:17 December 2015; Accepted:14 January 2016


We report multidrug-resistant Enterobacteriaceae in stool samples of unaccompanied refugee minors (<18 years-old) arriving in Frankfurt am Main, Germany, between 12 October and 6 November 2015. Of 119 individuals screened in this study, extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae were found in 42 (35%), including nine with additional resistance to fluoroquinolones (8% of total screened), i.e. 3-multidrug-resistant Gram-negative bacteria (MDR GNB).

Microbiological investigation

All unaccompanied refugee minors arriving without their parents and families in Frankfurt am Main, Germany, from 12 October to 6 November 2015 were screened for multidrug-resistant Enterobacteriaceae in stool samples with informed consent of their legal caregivers. The enterobacteria were classified as 3MDR GNB or 4MDR GNB according to the phenotypic definition of the German commission on hospital hygiene and infection prevention (Kommission für Krankenhaushygiene und Infektionsprävention), i.e. Enterobacteriaceae resistant against three of four antibiotic groups (penicillins with piperacillin as surrogate substance, cephalosporins with cefotaxime and/or ceftazidime as surrogate substance, and fluoroquinolones with ciprofloxacin as surrogate substance) were part of 3MDR GNB, while bacteria characterised as 4MDR GNB had additional resistance against carbapenems, with imipenem and/or meropenem as surrogate substance [1]. MDR GNB detection was performed by plating stools on ESBL and Klebsiella pneumoniae carbapenemase (KPC) chromagar selective media (Mast, Reinfeld, Germany). For identification and susceptibility testing of resistant colonies, matrix-assisted laser desorption ionization (MALDI), Biotyper mass spectrometry (Bruker Daltonics, Bremen, Germany) and VITEK 2 (BioMerieux, Nürtingen, Germany) with Clinical and Laboratory Standards Institute (CLSI) interpretative standards were used [2,3]. ESBL phenotypes were confirmed using double disk synergy testing [4]. Decreased carbapenem susceptibility in Enterobacteriaceae was confirmed using Etest and carbapenemase detection was performed using a modified Hodge test [2].

Laboratory findings

Of a total of 119 individuals screened, ESBL-producing Enterobacteriaceae were detected in 42 (35%), including nine 3MDR GNB (8% of total screened). No 4MDR GNB was observed. Six (5%) of the 119 refugees reported having a prior antimicrobial therapy, and two (2%) reported a hospital admission during the preceding six months. Among the 42 with ESBL-producing bacteria, two had received prior antimicrobial treatment in the past six months and one had been hospitalised, whereas one of nine refugees colonised with 3MDR GNB reported an antimicrobial treatment, with no hospital stay in this group.

In total, 37 Escherichia coli (thereof 9 3MDR GNB) and five K. pneumoniae (non-3MDR GNB) were detected. Whereas ESBL-producing bacteria were detected in persons from nearly all of the countries of origin (except Iraq, Iran, Libya, Senegal), 3MDR GNB were found only in persons coming from Afghanistan, Pakistan, and Somalia (Table).

Table

Detection of extended spectrum beta-lactamase-producing Enterobacteriaceae and thereof multidrug-resistant Gram-negatives in unaccompanied refugee minors arriving in Frankfurt am Main, Germany, 12 October–6 November 2015 (n=119)


Country of origin Number of persons tested Number of individuals with ESBL-producing Enterobacteriaceae Number of individuals with 3MDR GNB Number of individuals with 4MDR GNB
Afghanistan 80 34a 7b 0
Eritrea 9 1 0 0
Somalia 7 2 1 0
Syria 7 3 0 0
Ethiopia 5 0 0 0
Iraq 4 0 0 0
Pakistan 3 1 1 0
Yemen 1 1 0 0
Otherc 3 0 0 0
Total n (%) 119 42 (35)      9 (8) 0 (0)

ESBL: extended spectrum beta-lactamase; GNB: Gram-negative bacteria; MDR: multidrug-resistant.

a 29 Escherichia coli, 5 Klebsiella pneumoniae.

b 7 E. coli.

c Iran, Libya, Senegal.

Discussion and conclusion

There is a dramatic influx of refugees to the European Union under way, with more than 600,000 applications for asylum during the first nine months of 2015 in Germany [5]. Many refugees are coming from countries with high prevalence of multidrug-resistant organisms (MDRO) in hospital and community settings, such as Afghanistan, the Near and Middle East and the North African countries [6]. Additionally, many of the refugees coming from the Near and Middle East have been travelling through countries with high prevalences of MDROs, such as Turkey or Greece [7-9], whereas those coming from Africa are travelling via the ‘West-Route’, i.e. via Libya and Italy. A current European Centre for Disease Prevention and Control (ECDC) report showed high prevalence of carbapenem resistance and other antimicrobial resistances in Turkey and Greece in the period from 2013 to 2014 [7-9]. On that account, the Robert Koch Institute, Germany, has recommended in October 2015, screening refugees for MDRO on hospital admission in Germany [10]. Preliminary work on screening of 143 refugees admitted to the University Clinic of Frankfurt, Germany has been undertaken [11], however no data have so far been available on MDR GNB prevalences in young healthy refugees.

Here we report the first data on prevalence of 3MDR GNB and ESBL-producing bacteria in unaccompanied refugee minors arriving in the country. ESBL-producing Enterobacteriaceae were found in 35% of the individuals included in our study and among these, 3MDR GNB were found in 8% of the total individuals screened. To compare with estimates for the German population, between 2009 and 2012, Valenza et al. had tested 3,344 persons residing in the southern part of Germany, with 6.3% exhibiting ESBL, including 3MDR GNB, which occurred in 1.8% of those tested [12]. The MDR GNB prevalence in the young refugees exceeded these values by four- to fivefold.

In the Rhine-Main region, Germany, in the 2012 to 2015 period, prevalences for ESBL-producing bacteria and for 3MDR GNB were respectively 7.5% and 3.8% in dialysis outpatients, and 7.7% and 3.8% in patients of rehabilitation clinics, i.e. only slightly exceeding the MDR GNB prevalences in the general population [13,14]. Patients depending on ambulatory care or residing in elderly care homes however, were more frequently colonised with bacteria having an ESBL phenotype or 3MDR GNB, with, in outpatients, 14.4% ESBL-producing bacteria and 7.6% 3MDR GNB, and in nursing home residents, 17.8 to 26.7% ESBL-producing bacteria and 12.3 to 21.3% 3MDR GNB [15-17]. Hence, colonisation with ESBL-producing Enterobacteriaceae in the unaccompanied refugee minors was also exceeding rates of bacteria with ESBL in all other patient groups tested in the Rhine-Main region recently, and 3MDR GNB colonisation rates were exceeding those in haemodialysis and rehabilitation patients with regular contact to the German medical system as well.

Prevalence of ESBL-producing Enterobacteriaceae in unaccompanied minors was higher than prevalence rates of patients transferred from hospitals abroad to the University Hospital Zurich, Switzerland, from 1 January 2009 to 30 September 2011: of them, 13.9% were found with ESBL-producing bacteria, while 3MDR GNB prevalence was comparable (7.6% refugees compared with 8.1% patients transferred to the university clinic) [18]. However, prevalence of 3MDR GNB in the unaccompanied minors was still low compared with the data obtained by Reinheimer et al., who tested 143 refugee patients on admission to the University Hospital Frankfurt, Frankfurt/Main, Germany from June to December 2015 and compared the results to data on 1,489 non-refugee patients screened on admission as well. Prevalence of MDR GNB (ESBL-producing bacteria, 3MDR GNB, and 4MDR GNB) in refugee patients was 60.8%, and thus exceeding the prevalence of MDR GNB in non-refugees (16.7%) fourfold [11]. Our sample, however, encompassed only young people, most of them healthy, having fled on their own without their parents or families. This might explain the lower prevalence of MDR GNB in this group compared with that of the refugees on hospital admission. Nevertheless, both data support the demand for surveillance in refugees, not only for communicable disease [19] but also for MDRO [10].


Conflict of interest

None declared.

Authors’ contributions

Prof. Heudorf and Dr. Niels Kleinkauf wrote and finalised the paper, Dr. Krackhardt and Mrs. Karathana organised the study. Dr. Zinn was responsible for the analytical results.


References

  1. Hygienemaßnahmen bei Infektionen oder Besiedlung mit multiresistenten gramnegativen Stäbchen. Empfehlung der Kommission für Kranken-haushygiene und Infektionsprävention (KRINKO) beim Robert Koch-Institut (RKI). [Hygiene measures for infection or colonization with multidrug-resistant gram-negative bacilli. Commission recommendation for hospital hygiene and infection prevention (KRINKO at the Robert Koch Institute RKI)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2012;55(10):1311-54.PMID: 23011096

  2. Clinical and Laboratory Standards Institute (CSLI). Performance standards for antimicrobial susceptibility testing; twentyfifth informational supplement. Wayne, Pa: CSLI;2015. CLSI document M100-S25.

  3. El-Bouri K, Johnston S, Rees E, Thomas I, Bome-Mannathoko N, Jones C,  et al.  Comparison of bacterial identification by MALDI-TOF mass spectrometry and conventional diagnostic microbiology methods: agreement, speed and cost implications. Br J Biomed Sci. 2012;69(2):47-55.PMID: 22872927

  4. Wiegand I, Geiss HK, Mack D, Stürenburg E, Seifert H. Detection of extended-spectrum beta-lactamases among Enterobacteriaceae by use of semiautomated microbiology systems and manual detection procedures.J Clin Microbiol. 2007;45(4):1167-74. DOI: 10.1128/JCM.01988-06 PMID: 17287329

  5. European Asylum Support Office (EASO). Latest asylum trends. Number of applications for international protection in the EU+1. Valetta: EASO; September 2015. Available from: https://easo.europa.eu/wp-content/uploads/Latest-Asylum-Trends-snapshot-Sept-2015.pdf

  6. World Health Organization (WHO). Antimicrobial resistance. Global Report on Surveillance. Geneva: WHO; 2014. Available from: http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf?ua=1

  7. European Centre for Disease Prevention and Control (ECDC). Antimicrobial resistance surveillance in Europe 2014. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2015. Available from: http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-europe-2014.pdf

  8. Albiger B, Glasner C, Struelens MJ, Grundmann H, Monnet DL, European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) working group. Carbapenemase-producing Enterobacteriaceae in Europe: assessment by national experts from 38 countries, May 2015.Euro Surveill. 2015;20(45):30062.PMID: 26675038

  9. European Centre for Disease Prevention and Control (ECDC). Communicable disease risks associated with the movement of refugees in Europe during the winter season – 10 November 2015. Stockholm: ECDC; 2015. Available from: http://ecdc.europa.eu/en/publications/Publications/refugee-migrant-health-in-european-winter-rapid-risk-assessment.pdf

  10. Robert Koch-institute (RKI). Screening von Asylsuchenden auf Multiresistente Erreger (MRE). [Screening of refugees for multi-drug resistant bacteria]. Berlin: RKI; Oct 2015. [Accessed 5 Dec 2015]. German. Available from: http://www.rki.de/DE/Content/Gesundheitsmonitoring/Gesundheitsberichterstattung/GesundAZ/Content/A/Asylsuchende/Inhalt/MRE-Screening_Asylsuchende.pdf?__blob=publicationFile

  11. Reinheimer C, Kempf V, Göttig S, Hogardt M, Wichelhaus T, O´Rourke F, et al. Multidrug-resistant organisms detected in refugee patients admitted to a University Hospital, Germany June–December 2015.Euro Surveill. 2016;21(2):30110. DOI: 10.2807/1560-7917.ES.2016.21.2.30110

  12. Valenza G, Nickel S, Pfeifer Y, Eller C, Krupa E, Lehner-Reindl V,  et al.  Extended-spectrum-β-lactamase-producing Escherichia coli as intestinal colonizers in the German community. Antimicrob Agents Chemother. 2014;58(2):1228-30. DOI: 10.1128/AAC.01993-13 PMID: 24295972

  13. Dawson A, Mischler D, Petit C, Klein R, Heudorf U, Herrmann M. Prevalence of Methicillin-resistent Staphylococcus aureus in end stage renal failure patients in Saarland and Hessen.Int J Med Microbiol. 2012;302:87.

  14. Heudorf U, Färber D, Mischler D, Schade M, Zinn C, Cuny C,  et al.  [Multidrug-Resistant Organisms (MDRO) in Rehabilitation Clinics in the Rhine-Main-District, Germany, 2014: Prevalence and Risk Factors]. Rehabilitation (Stuttg). 2015;54(5):339-45.DOI: 10.1007/s00103-013-1927-7 PMID: 24658671

  15. Hogardt M, Proba P, Mischler D, Cuny C, Kempf VA, Heudorf U. Current prevalence of multidrug-resistant organisms in long-term care facilities in the Rhine-Main district, Germany, 2013.Euro Surveill. 2015;20(26):21171. DOI: 10.2807/1560-7917.ES2015.20.26.21171 PMID: 26159310

  16. Heudorf U, Gustav C, Mischler D, Schulze J. Nosokomiale Infektionen, systemischer Antibiotikaeinsatz und multiresistente Erreger bei Bewohnern von Altenpflegeheimen. [Healthcare associated infections (HAI), antibiotic use and prevalence of multidrug-resistant bacteria (MDRO) in residents of long-term care facilities: the Frankfurt HALT plus MDRO project 2012]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014;57(4):414-22. DOI: 10.1007/s00103-013-1927-7 PMID: 26505186

  17. Neumann N, Mischler D, Cuny C, Hogardt M, Kempf VAJ, Heudorf U. Multidrug-resistant organisms (MDRO) in patients in outpatient care in the Rhine-Main district, 2014: Prevalence and risk factors.Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2015. PMID:26631014

  18. Nemeth J, Ledergerber B, Preiswerk B, Nobile A, Karrer S, Ruef C,  et al.  Multidrug-resistant bacteria in travellers hospitalized abroad: prevalence, characteristics, and influence on clinical outcome. J Hosp Infect. 2012;82(4):254-9. DOI: 10.1016/j.jhin.2012.08.017 PMID: 23103249

  19. Catchpole M, Coulombier D. Refugee crisis demands European Union-wide surveillance!Euro Surveill. 2015;20(45):30063.PMID: 26606945



Back to Table of Contents
Previous Download (pdf)
Next

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN 1560-7917] - ©2007-2016. All rights reserved.
 

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.